Honolulu: Potential New Gene on the ALS List
Researchers at the University of Michigan reported today on a new gene they suspect of contributing to amyotrophic lateral sclerosis (ALS)...
ALL NEWS
6377 RESULTS
Sort By:
- Most Recent
- Most Commented
Natural Antibodies in AD Patients: Are Some Protective?
People produce different antibodies to different antigens, and those with Alzheimer's disease (AD) are no exception...
Research Brief: Secretory Hormones—Example of Functional Amyloid?
Though it remains a prime pathological hallmark of Alzheimer disease, Aβ amyloid has yet to convincingly prove itself as the major toxic species driving AD...
Aβ and Tau MARK Synapses for Dysfunction
A new study strengthens the connection between amyloid-β (Aβ) and tau, the two proteins most studied in Alzheimer’s disease (AD)...
Research Brief: Links in the Chain Between Amyloid-β and LTP
Indications are that amyloid-β destroys memory by disrupting synaptic plasticity...
Small STEP in Mice—Dare We Say Leap for AD?
Could the field be one step closer to a new potential therapy for AD? Possibly, if the target is striatal-enriched tyrosine phosphatase (STEP)...
Patient-Derived Aβ Needs Prion Protein to Harm Synapses
Scientists in Ireland have produced what could be the best evidence to date that cellular prion protein (PrPc) mediates Aβ’s dirty work in neurons...
Optimizing CSF Aβ42 ELISA for Trials and Regulatory Approval
Testing a widely used cerebrospinal fluid Aβ42 immunoassay, scientists proposed modifications that they believe improve its precision and accuracy...
α-Synuclein Appears to Regulate Synaptic Vesicles
The neuronal peptide α-synuclein is an important constituent of the Lewy bodies, pathological hallmarks of the Lewy body variant of Alzheimer's disease, as well as of Parkinson's and several other neurodegenerative diseases...
San Diego: α-Synuclein Protofibrils Create Sense of Déjà Vu in PD, DLB
In some ways, Alzheimer disease research is about a decade ahead of research on Parkinson’s...
β-Secretase a Clean Therapeutic Target
The most promising target for an Alzheimer's therapy in the short term may be the enzyme β-secretase, suggest two papers in the March issue of Nature Neuroscience. Two separate groups have found that mice lacking the BACE1...
Does Brain Hypoxia Help Kick Off Alzheimer’s Pathology?
Two new human studies implicate loss of oxygen in the brain as a possible culprit that touches off early AD pathology...
New Takes on Tau: Does It Stabilize Actin, Flag Neurogenesis?
Much as tau appears loath to give up its secrets, two recent papers reveal new...
Keystone: Diagnosis and Model Treatments for Traumatic Brain Injury
Identifying injuries that might lead to chronic traumatic encephalopathy or other neurodegenerative pathologies, and then treating those injuries, are two major challenges...
Paris: Studies Strengthen Link Between Brain Injury and Dementia
Some studies have shown that athletes who suffer repeated concussions develop a form of brain degeneration, different from AD, known as chronic traumatic encephalopathy...
Current Filters
- Date Range : All x